The open-label, prospective study (GRECCO-19) assessed the effect of treatment with low-dose colchicine on cardiac and inflammatory biomarkers as well as clinical outcomes.
For patients with moderate to severe COPD, dual bronchodilator therapy with a LABA plus a LAMA was found to improve lung function without increasing adverse events.
For a small group of nonhospitalized patients with coronavirus disease 2019, self-administration of high-dose oral famotidine was found to be associated with improvements in disease-related symptoms.
Researchers compared trends in the average weekly prescriptions of hydroxychloroquine/chloroquine, azithromycin, and 10 commonly used medications dispensed between February 16 and April 25, 2020 with those dispensed between February 17 and April 27, 2019.
Treatment with remdesivir was associated with a shorter time to recovery in patients hospitalized with coronavirus disease 2019.
A total of 108 healthy adult volunteers 18 to 60 years old (mean age, 36.3 years old) with no history of COVID-19 infection were enrolled in the study.
The use of immune globulin therapy appears to benefit children who experience acute heart failure caused by coronavirus disease 2019 (COVID-19)-related multisystem inflammatory syndrome, according to the findings of a case series recently published in Circulation.
Treatment with inhaled nitric oxide has been shown to have both pulmonary and antiviral benefits.
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
Recommendations on the management of coronavirus disease 2019 were recently released by the National Institutes of Health to help guide clinicians caring for patients with COVID-19.
